LinkedIn Image

Evolutionary Strategies in Acute Myeloid Leukemia

How Genetics and Genomics Inform Therapeutic Decisions

Meeting Overview

During this live symposium, experts will discuss new and evolving strategies available for patients with acute myeloid leukemia (AML). Tailoring treatment based on patient fitness, disease characteristics, and treatment goals is necessary for optimal outcomes. With several new agents in late-stage development, this symposium will review their efficacy and safety data and how to incorporate these agents into your clinical practice. Topics will include de novo, secondary, and relapsed/refractory AML. Clinical case scenarios will be presented and examined to learn from the experts.

A prIME Oncology satellite symposium to be held at the 23rd Congress of the European Hematology Association.


Thursday, 14 June

08.00 Welcome and introduction
Jorge Cortes, MD
08.03 Do you think like the experts?
Jorge Cortes, MD
08.08 Drilling down on the genomic landscape of AML
Adriano Venditti, MD
08.23 Q & A
08.28 Initial therapy for patients with de novo AML
Bob Löwenberg, MD, PhD
08.48 Q & A
08.53 Initial therapy for patients with secondary AML
Jorge Cortes, MD
09.08 Q & A
09.13 Strategies for relapsed/refractory AML
Nigel Russell, MD
09.28 Q & A
09.33 Evolving future strategies: A faculty panel discussion
Faculty Panel
09.48 Q & A
09.53 Repeat of “Do you think like the experts?”
Jorge Cortes, MD
09.58 Closing remarks
Jorge Cortes, MD
10.00 Adjourn


  • Jorge Cortes, MDThe University of Texas
    MD Anderson Cancer Center
    Houston, Texas, United States
  • Bob Löwenberg, MD, PhDErasmus University Medical Center
    Rotterdam, the Netherlands
  • Nigel Russell, MDNottingham University Hospitals NHS Trust
    Nottingham, United Kingdom
  • Adriano Venditti, MDUniversity of Rome "Tor Vergata"
    Rome, Italy

Target Audience

This educational activity is specifically designed to meet the needs of hematologists, oncologists, and other healthcare professionals involved in the management of patients with AML.

Learning Objectives

After successful completion of this educational activity, participants should be able to:

  • Develop treatment strategies for patients with AML using standard therapies as well as new/emerging agents
  • Differentiate the factors that impact treatment choice among de novo, secondary, and relapsed/refractory AML
  • Discuss efficacy and safety data of new/emerging treatment options that may be useful for patients with AML, and determine how these agents may best fit into treatment plans
Register Me

Date and Location

Thursday, 14 June 2018
08.00 – 10.00

Room: K1
Mässvägen 1
Älvsjö, Sweden

Printed Materials

Printed Materials


This activity is provided by prIME Oncology.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


prIME Oncology designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Good CME



This activity is supported by an educational grant from Jazz Pharmaceuticals.

Sunshine Act/EFPIA

prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.